Screener
Arcus Biosciences RCUS Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Types of securities as of June 30, 2026 | Amortized Cost | Unrealized Gain | Unrealized Loss | Fair Value |
|---|---|---|---|---|
| Money market funds | $138 | — | — | $138 |
| U.S. treasury securities | 222 | — | — | 222 |
| Corporate securities and commercial paper | 407 | — | (1) | 406 |
| Certificate of deposit | 9 | — | — | 9 |
| Total cash, cash equivalents and marketable securities | $776 | — | $(1) | $775 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's unrealized losses on investments (before tax)?
- Arcus Biosciences (RCUS) reported unrealized losses on investments (before tax) of $1M in Q2 2026.
- What is the long-term trend for Arcus Biosciences's unrealized losses on investments (before tax)?
- Over 3 years (2022 to 2025), Arcus Biosciences's unrealized losses on investments (before tax) has grown at a -100.0% compound annual growth rate (CAGR), from $7M to $0.
- What does unrealized losses on investments (before tax) mean?
- The total unrealized losses on investments, typically related to available-for-sale securities, before considering tax effects.
Ask your AI about Arcus Biosciences's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude